{"id":52508,"date":"2026-03-31T14:04:18","date_gmt":"2026-03-31T14:04:18","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/52508\/"},"modified":"2026-03-31T14:04:18","modified_gmt":"2026-03-31T14:04:18","slug":"novo-nordisk-unveils-discount-plan-to-challenge-obesity-drug-rivals","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/52508\/","title":{"rendered":"Novo Nordisk Unveils Discount Plan to Challenge Obesity Drug Rivals"},"content":{"rendered":"<p>&#13;<\/p>\n<p>Novo Nordisk is stepping up its competitive game in the obesity-drug market by introducing a new discounted subscription plan for U.S. Wegovy patients who are self-paying. The initiative aims to make the drug more accessible, with monthly costs slashed by almost 30% compared to its standard pricing.<\/p>\n<p>Facing pricing pressures in the booming market, especially against rival Eli Lilly, Novo Nordisk is collaborating with telehealth companies to market its drug more effectively. The plan offers three-, six-, and twelve-month subscriptions at reduced rates, along with broadened access via platforms like Ro, WeightWatchers, and LifeMD.<\/p>\n<p>Ed Cinca, Novo&#8217;s senior vice president of marketing, underscores the evolving role of patients into consumers demanding straightforward pricing and budgeting. This move, part of a broader strategy, reflects the company&#8217;s shift towards more consumer-oriented healthcare solutions, as it navigates the competitive landscape.<\/p>\n<p>&#13;<\/p>\n","protected":false},"excerpt":{"rendered":"&#13; Novo Nordisk is stepping up its competitive game in the obesity-drug market by introducing a new discounted&hellip;\n","protected":false},"author":2,"featured_media":36965,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[24073,276,2016,272,7979,358,29037,29036,360,1910],"class_list":["post-52508","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-consumer-market","tag-eli-lilly","tag-healthcare","tag-novo-nordisk","tag-obesity-drug","tag-pharmaceuticals","tag-pricing-strategy","tag-subscription-plan","tag-telehealth","tag-wegovy"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116324169589534383","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/52508","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=52508"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/52508\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/36965"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=52508"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=52508"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=52508"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}